Lumos Diagnostics Partners with US Medical Technology Firm to Support US Commercialization; Shares Up 12%

MT Newswires Live

Nov 20, 2025

Lumos Diagnostics (ASX:LDX) partnered with AcuityMD to support the US commercialization of its FebriDx test through enhanced visibility into reimbursement performance under the Proprietary Laboratory Analyses Code #0442U, according to a Thursday filing with the Australian bourse.

AcuityMD will use its artificial intelligence-enabled platform to work with the company's US commercial collaborator, PRO-spectus, to analyze data from patients to ensure field efforts are leading to the desired reimbursement and repeat business outcomes for FebriDx, the filing said.

Lumos Diagnostics shares rose 12% in midday trade on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584080389"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584080389\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584080389?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584080389","market":"hk","top_or_hot":-1,"title":"Lumos Diagnostics Partners with US Medical Technology Firm to Support US Commercialization; Shares Up 12%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> (ASX:LDX) partnered with AcuityMD to support the US commercialization of its FebriDx test through enhanced visibility into reimbursement performance under the Proprietary Laboratory Analyses Code #0442U, according to a Thursday filing with the Australian bourse.</p><p>AcuityMD will use its artificial intelligence-enabled platform to work with the company's US commercial collaborator, PRO-spectus, to analyze data from patients to ensure field efforts are leading to the desired reimbursement and repeat business outcomes for FebriDx, the filing said.</p><p><a href=\"https://laohu8.com/S/LDX.AU\">Lumos Diagnostics</a> shares rose 12% in midday trade on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lumos Diagnostics Partners with US Medical Technology Firm to Support US Commercialization; Shares Up 12%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLumos Diagnostics Partners with US Medical Technology Firm to Support US Commercialization; Shares Up 12%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-20 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> (ASX:LDX) partnered with AcuityMD to support the US commercialization of its FebriDx test through enhanced visibility into reimbursement performance under the Proprietary Laboratory Analyses Code #0442U, according to a Thursday filing with the Australian bourse.</p><p>AcuityMD will use its artificial intelligence-enabled platform to work with the company's US commercial collaborator, PRO-spectus, to analyze data from patients to ensure field efforts are leading to the desired reimbursement and repeat business outcomes for FebriDx, the filing said.</p><p><a href=\"https://laohu8.com/S/LDX.AU\">Lumos Diagnostics</a> shares rose 12% in midday trade on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7126","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2584080389","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584080389","pubTimestamp":1763602475,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lumos Diagnostics  partnered with AcuityMD to support the US commercialization of its FebriDx test through enhanced visibility into reimbursement performance under the Proprietary Laboratory Analyses Code #0442U, according to a Thursday filing with the Australian bourse.AcuityMD will use its artificial intelligence-enabled platform to work with the company's US commercial collaborator, PRO-spectus, to analyze data from patients to ensure field efforts are leading to the desired reimbursement and repeat business outcomes for FebriDx, the filing said.Lumos Diagnostics shares rose 12% in midday trade on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7126":"医疗保健用品","LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L"},"translate_title":"Lumos Diagnostics与美国医疗技术公司合作支持美国商业化；股价上涨12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LDX.AU":1},"content_text":"Lumos Diagnostics (ASX:LDX) partnered with AcuityMD to support the US commercialization of its FebriDx test through enhanced visibility into reimbursement performance under the Proprietary Laboratory Analyses Code #0442U, according to a Thursday filing with the Australian bourse.AcuityMD will use its artificial intelligence-enabled platform to work with the company's US commercial collaborator, PRO-spectus, to analyze data from patients to ensure field efforts are leading to the desired reimbursement and repeat business outcomes for FebriDx, the filing said.Lumos Diagnostics shares rose 12% in midday trade on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}